Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly and Company is shifting away from using horseshoe ... except that we can make it in cells and we don’t need to derive that from horseshoe crab blood. This is a kind of a more recent ...

Eli Lilly and Novo Nordisk dominate the ... agonist candidate in phase 2 trials at the moment. Lilly's leap closer to the finish line But Lilly is ahead of the pack and just took a leap closer ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

a cutting-edge cancer treatment that targets specific cancer cells. This is just one example of the company’s diverse and promising pipeline. Eli Lilly and Company (NYSE:LLY) holds a strong ...

As for Eli Lilly’s 2025 outlook, it guided for full-year revenues between $58 billion and $61 billion, representing 32% growth at the midpoint. The company ... 7% (in-line with the broader ...